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1. Introduction 
Members of the human epidermal growth factor receptor (HER) family—epidermal growth 
factor receptor (EGFR, HER1), HER2, HER3, and HER4—are transmembrane tyrosine kinase 
receptors that are important mediators of cell growth, development, and survival. 
Activation of the HER tyrosine kinases triggers intracellular signaling pathways, including 
the MAPK and PI3K-Akt pathways (Olayioye et al., 2000) (Figure 1). 
 
 
(Amler, L.C. Expert Opinion on Biological Therapy, 2010; Vol.10, No.9, pp.1343-1344, copyright  2010, 
Informa Healthcare. Reproduced with permission of Informa Healthcare)  
Fig. 1. Dimerization of HER2–HER3 initiates the PI3K and MAPK signaling pathways. 
Ligand binding to HER1, 3, and 4 results in a conformational change in the extracellular 
domain of each protein that opens a dimerization domain and allows the receptor to form 
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either a homo- or heterodimer with another member of the HER family (Cho & Leahy, 2002; 
Zhang et al., 2006). No ligand has been identified for HER2, and it exists in a conformation 
that is constitutively available for dimerization (Garrett et al., 2003). HER2 is therefore the 
preferred dimer partner of other HER family members (Graus-Porta et al., 1997). While 
HER2 has no known ligand, HER3 lacks intracellular tyrosine kinase activity, rendering 
HER2–HER3 signaling dependent on heterodimerization (Yarden & Sliwkowski, 2001). 
HER2–HER3 dimerization results in phosphorylation of the tyrosine kinase domain, which 
in turn activates intracellular signaling pathways (Zhang et al., 2006). The effect of these 
signaling pathways on gene transcription determines how the cell responds to the ligand 
activation. 
HER family members can also be activated by ligand-independent mechanisms, including 
activation by other tyrosine kinase receptors, G-protein coupled receptors, and adhesion 
proteins (Siwak et al., 2010). 
1.1 Role of HER2 in oncology 
Members of the HER family were first associated with oncogenesis after the discovery that 
the sequence of the EGFR receptor was found to be very similar to that of v-ErbB, a 
transforming retroviral oncogene carried by the avian erythroblastosis virus (Downward et 
al., 1984). The v-ErbB oncogene encodes a truncated form of EGFR that can form ligand-
independent dimers, thereby initiating cell signaling pathways and inducing cellular 
proliferation in the absence of ligand stimulation (Adelsman et al., 1996). Examination of a 
series of rat neuro/gliobalstomas revealed a commonly transforming gene, neu, encoding a 
protein serologically related to ErbB (EGFR), subsequently shown to be the HER2 
oncoprotein (Coussens et al., 1985; Schechter et al., 1984). 
HER2 expression is frequently dysregulated in several types of human tumors including 
those of the breast, head and neck, prostate, and ovary (Hynes, 1993). Of particular 
significance was the discovery that the HER2 protein was overexpressed, commonly by 
gene amplification, in about 30% of breast cancers. These studies also showed that 
overexpression of HER2 indicated  an aggressive subtype of breast cancers with a 
particularly poor prognosis for the patient (Slamon et al., 1987, 1989). Overexpression of 
HER2 facilitates the formation of HER2 heterodimers, which trigger HER2 signaling 
pathways (Yarden and Sliwkowski, 2001), with excess HER2 signaling resulting in signaling 
cascades that promote oncogenic cell survival and proliferation (Olayioye et al., 2000; 
Rowinsky, 2004).  
HER2 amplification /overexpression has also been reported in patients with gastric tumors 
where it is again linked to a poor prognosis (Jaehne et al., 1992). In addition, increased HER2 
levels have been reported in some patients with salivary gland tumors (Cornolti et al., 2007) 
and non-small cell lung cancer (NSCLC) (Cappuzzo et al., 2006). Mutations in tumor 
suppressor genes may be partly responsible for the aberrant expression of HER2 in these 
tumors. Foe example, one tumor suppressor, FOXP3, normally maintains low levels of 
HER2 in normal cells; however, in breast cancer models the absence of FOXP3 results in 
high expression of HER2 (Zuo et al., 2007). 
Overexpression of HER2 is only one of several mechanisms, albeit the most frequent, by 
which HER2 signaling can be activated in oncogenesis. Mutations in the kinase domain of 
HER2 can potentially trigger signaling that is independent of ligand binding or dimerization 
(Anglesio et al., 2008). Ligand-dependent activation of HER2 via dimerization with other 
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HER family members may also play a role in HER2 oncogenesis. Of all of the different HER 
family dimers, the HER2–HER3 heterodimer appears to have the most potent signaling 
effects in cancer cells (Tzahar et al., 1996).. It appears that HER3 is crucial for mediating the 
dysregulated signaling in tumors overexpressing HER2 (Lee-Hoeflich et al., 2008). Cancers 
with HER2 amplification are frequently observed to have increased Akt activity even 
though HER2 cannot directly activate the PI3K–Akt pathway (Hsieh & Moasser, 2007). 
However, the intracellular domain of HER3 contains several binding sites for PI3K, enabling 
direct activation of the PI3K–Akt pathway (Figure 1), which may explain the mitogenic 
activity of HER2–HER3 dimers (Hsieh & Moasser, 2007). HER2 can also form a dimer with 
EGFR, which initiates intracellular signaling via the MAPK pathway (Campiglio et al., 1999). 
In summary, while HER2 amplification leading to overexpression is clearly linked to 
activation of HER2 in some tumor cells, activating mutations in HER2, as well as ligand-
dependent activation of HER2 signaling, are also likely important mechanisms leading to 
HER2 oncogenesis. 
2. HER2 in ovarian cancer 
The HER family are important mediators of normal ovarian follicle development, and 
regulate the growth of ovarian epithelial cells (Conti et al., 2006). Dysregulation of HER 
signaling in the ovary due to overexpression of, or mutations in HER family members have 
been linked to the growth and proliferation of ovarian tumors. 
2.1 HER2 overexpression in ovarian cancer 
The proportion of ovarian cancers overexpressing HER2 is a matter of debate (Sheng & Liu, 
2011). Various studies have reported that between 5% and 35% of ovarian tumors 
overexpress HER2 (Table 1). Some of these differences are likely to be attributable to the 
diagnostic technique used to measure HER2 expression. HER2 protein expression is 
commonly measured using immunohistochemistry (IHC), whereas HER2 gene amplification 
is typically measured using hybridization techniques, such as fluorescence in situ 
hybridization (FISH) (Wolff et al., 2007). Recent technical improvements also enable 
measurement of HER2 mRNA expression levels using the quantitative real time-polymerase 
chain reaction (qRT-PCR) in archival samples (Muller et al., 2011).  
However, the reported levels of HER2 overexpression and/or amplification may be affected 
by other factors including variable definitions of overexpression, small sample sizes, and 
variable testing conditions or assay performance (Wolff et al., 2007). It should also be noted 
that studies investigating only HER2 gene amplification are likely to account for only a 
proportion of cancers that overexpress of the protein without amplification of the gene 
(Mano et al., 2004). 
In a  recent study of somatic copy number alterations in 489 ovarian cancer samples using 
multiple microarray-based platforms, 63 regions of recurrent focal amplification were 
identified, of which 26 regions encoded eight or fewer genes. The most common focal 
amplifications encoded CCNE1, MYC, and MECOM, each of which was highly amplified in 
more than 20% of tumors. By contrast, HER2 was highly amplified in 3.1% of tumors, and a 
further 7% of tumors had a more moderate level of HER2 amplification. The correlation 
between HER2 copy number and mRNA expression was 0.59 (Cancer Genome Atlas 
Research Network, 2011). 
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Study 
Method 
of assay 
Pts with HER2-
positive tumors,  
n/N (%) 
Definition of ‘HER2-
positive’ 
Correlation between 
expression and 
survival1? 
Yes/No p-value 
Rubin et al., 
1993 
IHC 
36/105 (34) 2+ or 3+ membrane staining 
No†‡ NA 
12/105 (11) 1+ membrane staining 
Meden et al., 
1994 
IHC 51/275 (19) NS Yes 
p=0.001† 
p=0.006‡ 
Meden et al., 
1995 
IHC 48/266 (18) NS Yes 
p=0.002† 
p=0.012‡ 
Meden et al., 
1998 
IHC 46/208 (22) 
>5% cells had membrane 
staining at 100× 
magnification 
Yes p=0.0003† 
Bookman et 
al., 2003 
IHC 95/837 (11) 2+ or 3+ membrane staining NA NA 
Hogdall et al., 
2003 
IHC 
24/181 (13) 2+ or 3+ membrane staining 
Yes p=0.003‡ 
71/181 (39) 1+ membrane staining 
Cloven et al., 
2004 
IHC 227/1420 (16) ≥1+ staining NA NA 
Lassus et al., 
20042 
IHC 66/390 (17) 2+ or 3+ membrane staining Yes p<0.0001† 
CISH 
26/381 (7) 
>5 copies of HER2 per 
nucleus 
Yes 
p<0.0001† 
p<0.006‡ 
55/381 (14) 
3–5 copies of HER2 per 
nucleus 
Kupryjanczyk 
et al., 2004 
IHC 
63/233 (27) 2+ or 3+ membrane staining 
No NA 
35/233 (15) 1+ membrane staining 
Nielsen et al., 
2004  
IHC 272/783 (35) 
2+ or 3+ staining of 
cytoplasm or membrane 
Yes/No 
p=0.021†3 
p=0.76‡ 
Lee et al., 
2005 
IHC 5/102 (5) ≥1+ staining NA NA 
Verri et al., 
2005 
IHC 
27/194 (14) 2+ or 3+ membrane staining 
Yes/No 
p=0.04† 
p<0.30‡ 26/194 (13) 1+ membrane staining 
Steffensen et 
al., 20072 
IHC 
18/160 (11) 2+ or 3+ membrane staining 
Yes p=0.03† 
39/160 (24) 1+ membrane staining 
FISH 10/145 (7) HER2:CEP17 ratio >2 No p=0.39† 
Tuefferd et 
al., 2007 
IHC 41/320 (13) 2+ or 3+ membrane staining No 
p=0.6† 
p=0.152‡ 
Farley et al., 
2009 
FISH 
9/133 (7) HER2:CEP17 ratio >2 No 
p=0.12† 
p=0.152‡ 
12/133 (9) HER2:nuclei ratio >4 No 
p=0.42† 
p=0.980‡ 
CEP17, chromosome enumeration probe 17; CISH, chromogenic in situ hybridization; FISH; 
fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, 
immunohistochemistry; NA, not applicable; NS, not specified; Pts, patients. 
1 Overall survival of patients with HER2 positive tumors versus those with HER2 negative tumors. † 
Univariate analysis; ‡ Multivariate analysis.  
2 Not all IHC samples were analyzable by CISH/FISH due to DNA degradation. 
3 Patients with HER2 positive tumors had increased survival versus those with HER2 negative tumors. 
Table 1. Expression level of HER2 in ovarian tumors in studies with >100 patients. 
www.intechopen.com
 
HER2 as a Therapeutic Target in Ovarian Cancer 
 
293 
The HER2 mRNA level in samples taken from ovarian tumors of patients who were enrolled 
in a clinical trial studying platinum-sensitive disease (Kaye et al., 2008) showed a 
dichotomous distribution of HER2 mRNA expression (Figure 2A) similar to that observed in 
tumor samples from a study of patients with breast cancer (Figure 2B) (Burris et al., 2011). 
The prevalence of mRNA overexpression in the ovarian cancer samples was approximately 
5% (Yulei Wang & Lukas Amler, unpublished data).  
 
A B 
HER2 
Overexpression 
HER2 
Overexpression 
 
Fig. 2. Distribution of HER2 mRNA expression levels in (A) ovarian cancer and (B) breast 
cancer (Yulei Wang & Lukas Amler, unpublished data).  
Samples from ovarian tumors were randomly chosen from archived samples collected 
during a clinical trial (Kaye et al., 2008). Samples from breast tumors were also collected 
during a clinical trial (Burris et al., 2011) but had known HER2 status (75% were HER2 
negative, 25% were HER2 positive by IHC). HER2 mRNA levels in both data sets were 
determined by qRT-PCR (method as published in Makhija et al., 2010).  
The CR of HER2:G6PDH expression was plotted as a histogram, and a smooth curve was 
fitted over the histogram. The ovarian cancer samples show a bimodal distribution of HER2 
expression, with a small peak indicating the population of tumors that overexpress HER2 
mRNA. 
(BC, breast cancer; CR, concentration ratio; HER2, human epidermal growth factor 
receptor 2; G6PDH, glucose-6-phosphate dehydrogenase; IHC, immunohistochemistry; 
qRT-PCR, quantitative real time-polymerase chain reaction). 
Steffenson et al. also used qRT-PCR to measure HER2 mRNA expression in 99 ovarian 
tumors and found that the tumor tissue had an average 5.7-fold higher level of HER2 
mRNA compared with normal ovarian tissue. IHC showed HER2 overexpression (2+/3+ 
staining) in 11% (11/99) of tumors with a further 33% (33/99) of tumors showing 1+ 
staining. In contrast, all samples from normal ovarian tissue (n=23) were shown to be 
negative for HER2 staining (Steffensen et al., 2008). 
Several studies have shown that overexpression of HER2 in ovarian tumors is an 
independent predictor of shorter progression-free survival and/or overall survival after 
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multivariate analysis. However, this has not been supported by other studies (Table 1) 
(Serrano-Olvera et al., 2006). This discrepancy may indicate that while HER2 overexpression 
is of prognostic value in some groups of patients, this is not true for all patients in whom 
other biomarkers may be more significant. Assay quality, execution, and interpretation of 
data, as discussed above, may also explain differences in the observed levels of HER2 
expression and its prognostic value. 
2.2 Activation of HER2 in ovarian cancer 
HER2 amplification and/or overexpression occurs in relatively few patients with ovarian 
cancer, although “normal” expression of HER2 measured by IHC 1+ staining is relatively 
common (Table 1). Other mechanisms, such as mutations in HER2 or ligand-dependent 
activation of HER2, may play a role in HER2 oncogenesis. 
Mutations in the HER2 kinase domain are indeed found in ovarian tumors (Table 2), and the 
pattern of these in-frame insertions and missense mutations is similar to activating 
mutations found in other kinases, strongly suggesting that these mutations activate the 
HER2 kinase. For example, mutations in HER2 are adjacent to or overlap with the analogous 
structural region of EGFR in-frame deletions that are associated with some lung tumors 
(Stephens et al., 2004). One study found that 6% of serous borderline ovarian tumors of low 
malignant potential (LMP) expressed a mutated version of HER2. LMP ovarian tumors also 
have a high rate of KRAS (18%) and BRAF (48%) mutations indicating that constitutive 
activation of the RAS–MAPK pathway may be one of the key mechanisms in the 
development of this type of ovarian tumor (Anglesio et al., 2008).  
 
Nucleotide change 
Amino acid 
change 
Frequency 
n/N (%) 
Tumor subtype Reference 
c.2325_2326 
12 bp insertion 
p.A775_G776  
insert YVMA 
1/84 
(1) 
Serous borderline 
tumors 
Anglesio et 
al., 2008 
c.2322_2323 
12 bp insertion 
p.M774_A775  
insert AYVM 
2/84 
(2) 
Serous borderline 
tumors 
c.2324_2325 
12 bp insertion 
p.A775_G776  
insert YVMA 
2/84 
(2) 
Serous borderline 
tumors 
12 bp insertion 
between c.2313  
and c.2324 
NK 
2/21 
(10) 
Serous borderline 
tumors 
Nakayama 
et al., 2006 
c.2315_2316 
12 bp insertion 
p.A772_G773  
insert YVMA 
1/188 
(0.5) 
Serous carcinoma 
Lassus et 
al., 2006 
c.2327 
G>T 
p.G776V 
1/6 
(17) 
Ovarian cell lines 
Ikediobi et 
al., 2006 
c.2570 
A>G 
p.N857S 
1/27 
(4) 
Serous carcinoma 
Stephens et 
al., 2004 
c.2539 
C>G 
p.I767M 
1/58 
(2) 
Serous carcinoma 
Kan et al., 
2010 
bp, base pairs; NK, not known. 
Table 2. HER2 mutations in ovarian tumors and cell lines. 
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Ligand-dependent signaling via HER2–HER3 or HER2–EGFR dimers may also be important 
in ovarian cancer (Amler, 2010; Campiglio et al., 1999; Lewis et al., 1996). To investigate this 
hypothesis, Gordon et al. measured activated phosphorylated (p)HER2 by enzyme-linked 
immunosorbent assay and HER2 gene amplification by FISH in 20 fresh ovarian tumor 
biopsies. They found that while only two tumors had HER2 gene amplification (10%), 
pHER2 was detected in 45% of tumors (Gordon et al., 2006), indicating that activation of 
HER2 signaling probably occurs independently of gene amplification. 
2.3 Biomarkers to identify HER2 activated or dependent ovarian tumors 
Cumulative evidence over the past decade has demonstrated that in most cases, tumors 
from the same anatomic site of origin can be sub-classified into distinct molecular subsets 
driven by different underlying biological mechanisms and with distinct prognoses. This is 
best exemplified in breast cancer, where at least four distinct subtypes have been identified 
(Onitilo et al., 2009). Biomarkers that can differentiate between these distinct biological 
subsets of tumors can be used to predict the prognosis of a patient and potentially identify 
those who will derive the most benefit from targeted therapies (Carden et al., 2009). In 
breast cancer, such relevant biomarkers include measuring the expression of estrogen 
receptor α and the progesterone receptor to identify patients who would be sensitive to 
hormonal therapies, and HER2 to identify patients who would benefit from treatment with 
HER2-targeted therapies (Labuhn et al., 2006). Likewise, biomarkers are also used to 
determine the best course of treatment in a variety of other cancers. For example, patients 
with NSCLC or colorectal cancer (CRC) are screened for mutations in EGFR and KRAS, 
respectively, to determine whether they would benefit from EGFR inhibitors (Catenacci et 
al., 2011; Domingo et al., 2010). Mutations in both of these oncogenes are likely 
representative of distinct biological subsets of disease. For example, patients whose tumors 
harbor EGFR mutations are typically non-smokers, often female and of Asian ethnicity, and 
generally have a better prognosis than non-EGFR mutant NSCLC (Coate et al., 2009). 
The identification of patients with ovarian tumors that express either high levels of HER2, 
HER2 with activating mutations, or biomarkers that indicate activated HER2 signaling, such 
as pHER2, could enable the patients who would derive the greatest therapeutic benefit to 
receive HER2-targeted therapies. Measuring the expression status of genes regulated by 
HER2 signaling could also identify tumors with activated HER2 signaling.  
The importance of HER2–HER3 heterodimers in the HER2 signaling pathway has led to the 
investigation of HER3 as a prognostic biomarker in ovarian cancer (Amler, 2010). In one 
study of patients with ovarian cancer, those with high (≥ median; n=62) expression of HER3 
protein had significantly decreased survival compared with those with low (< median; 
n=54) expression levels (1.80 versus 3.31 years; p=0.0034) following surgery and 
chemotherapy. In multivariate analysis, high HER3 expression significantly increased the 
risk of mortality compared with low HER3 expression (p=0.018) (Tanner et al., 2006). In 
contrast, patients with ovarian cancer receiving gemcitabine who had low HER3 mRNA 
expression (< median; n=35) had a significantly decreased progression-free survival 
(p=0.0002) and overall survival (p=0.003) than patients with high HER3 (≥ median; n= 24) 
mRNA levels. These data suggest that HER3 may be a prognostic biomarker in ovarian 
cancer (Makhija et al., 2010). 
Interestingly, two separate studies have demonstrated that HER3 mRNA and protein levels 
in ovarian cancer cell lines were reduced on addition of heregulin, a ligand for HER3 
(Makhija et al., 2010; Nagumo et al., 2009). The modulation of HER3 mRNA levels was 
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found to be inversely proportional to activation of the downstream signaling molecules Akt 
and ERK1/2, critical components of the PI3K–Akt pathway (Nagumo et al., 2009). This 
suggests that low HER3 mRNA levels in HER2-positive tumors are associated with a high 
level of HER2–HER3 signaling. Overall these results point to a negative feedback loop that 
responds to the activation of HER3 by downregulation of HER3 mRNA expression (Makhija 
et al., 2010; Nagumo et al., 2009), and suggests that HER3 protein or mRNA levels may be a 
useful prognostic biomarker in patients with ovarian cancer. 
3. HER2 as a drug target in human cancer 
3.1 Clinical evidence for HER2 as a drug target in solid tumors 
Trastuzumab (Herceptin) is a monoclonal antibody that binds to HER2 in the 
juxtamembrane region of the extracellular domain (Cho et al., 2003). Trastuzumab is 
licensed for use as a first-line treatment in combination with other chemotherapeutic agents 
in patients with HER2-positive breast cancer or gastric cancer in the USA and Europe. It has 
also been licensed for use as a single agent in patients with breast cancer who have not 
responded to previous chemotherapy (Genentech Inc., 2011). A trial of trastuzumab in 
combination with other chemotherapies in 3351 patients with breast cancer demonstrated 
significant improvements in disease-free survival (p<0.0001) and overall survival (p=0.015) 
compared with patients receiving chemotherapeutic agents alone (Romond et al., 2005). 
Patients who received trastuzumab after chemotherapy also exhibited a significant 
improvement in disease-free survival compared with those who did not (p<0.0001) (Piccart-
Gebhart et al., 2005). In a Phase III trial of 584 patients with gastric cancer, the addition of 
trastuzumab to other chemotherapeutic agents significantly improved survival versus 
chemotherapy alone (p=0.0046) (Bang et al., 2010).  
Lapatinib (Tyverb/Tykerb) is a small molecule inhibitor that targets the tyrosine kinase 
domain of HER2 and EGFR, thereby inhibiting downstream signaling from both receptors. 
In a Phase III trial, lapatinib increased the time to disease progression from 4.4 months in 
patients on capecitabine monotherapy (n=161) to 8.4 months in patients on a combination of 
the two drugs (n=163; p<0.001) (Geyer et al., 2006). The addition of lapatinib to letrozole also 
significantly reduced the risk of disease progression versus letrozole monotherapy (p=0.019) 
in 219 patients with HER2-positive breast tumors (Johnston et al., 2009). Following these 
trials, lapatinib was licensed for use in combination with letrozole as a first-line treatment 
for HER2-positive breast cancer, and in combination with capecitabine as a second-line 
treatment for breast cancer in the USA and Europe (GlaxoSmithKline, 2011).  
A third agent targeting the HER2 signaling pathway, pertuzumab, is another monoclonal 
antibody that binds to the extracellular domain of HER2 and inhibits HER2 dimerization. 
The clinical development of pertuzumab is most advanced in breast cancer. In a Phase II 
trial of 66 patients with HER2-positive advanced breast cancer whose disease had 
progressed while on trastuzumab monotherapy, pertuzumab in combination with 
trastuzumab resulted in a complete response for 6% of patients. An additional 18% of 
patients had a partial response to therapy and 26% achieved stable disease for ≥6 months. 
Overall, 50% of patients benefited from the pertuzumab–trastuzumab combination (Baselga 
et al., 2010). Pertuzumab is currently undergoing several clinical trials for the treatment of 
HER2-positive breast cancer in combination with various other agents including 
trastuzumab (clinicaltrials.gov; Baselga & Swain, 2010). 
Other HER2-targeted therapies in development for cancer are shown in Table 3. 
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HER2-targeting 
agent 
Mechanism of 
action 
Clinical 
stage 
Cancer type 
Clinicaltrials.gov 
identifier 
Neratinib 
TKI 
Dual HER2/EGFR 
inhibitor 
Phase III Breast 
NCT00878709 
NCT00915018 
Afatinib 
TKI 
Dual HER2/EGFR 
inhibitor 
Phase III 
Breast 
 NSCLC 
NCT01125566 
NCT01121393 
Phase II 
CRC  
Prostate  
Glioma  
Head and neck 
NCT01152437 
NCT01320280 
NCT00727506 
NCT00514943 
Phase I 
Advanced solid 
tumors 
NCT01206816 
Varlitinib 
TKI 
Triple 
HER2/EGFR/ 
HER4 inhibitor 
Phase 
I/II 
Advanced solid 
tumors 
NCT00862524 
MGAH22 HER2 mAb Phase I 
NSCLC 
Prostate 
Bladder 
Ovarian 
Breast 
NCT01195935 
NCT01148849 
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2/4, human epidermal growth 
factor receptor 2/4; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; TKI, tyrosine 
kinase inhibitor. 
Table 3. HER2-targeted therapies in clinical testing for the treatment of cancer (data from 
clinicaltrials.gov). 
3.2 Preclinical evidence for HER2 as a target in ovarian cancer 
Trastuzumab, pertuzumab, and lapatinib have all been studied in cell and animal models of 
ovarian cancer, demonstrating the potential use of these therapies to treat patients.  
For example, in SKOV3 cells, a cell line derived from the ascites of an ovarian 
adenocarcinoma, trastuzumab has been shown to reduce pHER2 and pAkt levels, indicating 
that trastuzumab reduced the activation of HER2 signaling pathways (Larbouret et al., 
2007). Moreover, both trastuzumab and lapatinib have been shown to reduce the ability of 
SKOV3 cells to form spheres in a dose-dependent manner, suggesting that both agents have 
an effect on the growth or viability of ovarian cancer cells (Magnifico et al., 2009). 
Pertuzumab and trastuzumab have been shown to reduce HER2–EGFR dimerization in 
SKOV3 cells by 24% and 44%, respectively, while lapatinib had little effect on dimerization 
(Gaborit et al., 2011). Finally, trastuzumab was shown to reduce tumor progression of 
SKOV3 xenografts in mice (Larbouret et al., 2007; Magnifico et al., 2009).  
A number of studies have also investigated the effect of HER2 inhibitors on ligand-dependent 
signaling. Pertuzumab has been shown to reverse ligand-stimulated growth by inhibiting the 
phosphorylation of HER2 and subsequent activation of downstream signaling pathways 
(Mullen et al., 2007). Makhija et al. showed that HER3 mRNA expression was reduced by 
ligand stimulation in six of the eight ovarian cell lines tested. This effect was reversed by the 
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addition of pertuzumab, small interfering RNAs (siRNAs) targeting the HER2 transcript, or 
inhibition of PI3K activity using a small molecule inhibitor. In contrast, siRNAs targeting the 
EGFR transcript, or a MEK inhibitor were not able to suppress ligand stimulation, indicating 
that pertuzumab inhibits HER2–HER3 signaling (Makhija et al., 2010). In a separate study, 
down-regulation of HER3 mRNA by heregulin-dependent activation of HER3 was reversed by 
pertuzumab. These authors also demonstrated that a change in HER3 mRNA levels was 
accompanied by changes in Akt and ERK signaling (Nagumo et al., 2009).  
Other preclinical studies have suggested that levels of the HER2 extracellular domain may 
be a biomarker of response or resistance to some therapies used to treat ovarian cancer 
(Vazquez-Martin et al., 2011). 
3.3 Clinical evidence for HER2 as a target in ovarian cancer 
Trastuzumab, pertuzumab and lapatinib have also been studied in a number of clinical trials 
of ovarian cancer (Table 4). 
 
Drug Combination No. pts Clinical stage Reference 
Trastuzumab Monotherapy 41 Phase II Bookman et al., 2003 
Lapatinib 
Carboplatin 11 Phase I Kimball et al., 2008 
Carboplatin and 
paclitaxel 
21 Phase I/II Rivkin et al., 2008 
Topotecan 18 Phase II Weroha et al., 2011 
Pertuzumab 
Monotherapy 117 
Phase II 
Gordon et al., 2006 
Carboplatin 
with 
gemcitabine or 
paclitaxel 
84 Kaye et al., 2008 
Gemcitabine 130 Makhija et al., 2010 
Table 4. A summary of completed clinical trials of trastuzumab, lapatinib, and pertuzumab 
in HER2-positive ovarian cancer. 
3.3.1 Trastuzumab  
In HER2-positive ovarian cancer (2+/3+ staining by IHC), a Phase II trial of trastuzumab in 
41 patients demonstrated an overall response rate of 7% (3 patients). One patient had a 
complete response to trastuzumab, and two patients had partial responses to treatment, 
while a further 16 patients (39%) achieved stable disease (Bookman et al., 2003). There are no 
reports of further development of trastuzumab for the treatment of ovarian cancer. 
3.3.2 Lapatinib 
Although studies of lapatinib for the treatment of ovarian cancer are at a relatively early 
stage, available evidence suggests that lapatinib may be effective in some patients with 
ovarian cancer. Of 11 patients with platinum-sensitive ovarian cancer receiving lapatinib 
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plus carboplatin in a Phase Ib trial, three (27%) had a partial response to treatment and a 
further three patients achieved stable disease (Kimball et al., 2008). Rivkin et al. reported 
preliminary results from a Phase I/II study of lapatinib in combination with carboplatin and 
paclitaxel in 21 patients with ovarian cancer. Complete responses were observed in 21% of 
patients, with a further 29% of patients experiencing a partial response and 29% achieving 
stable disease (Rivkin et al., 2008). Lapatinib has also been studied in ovarian cancer in 
combination with topotecan. Results from this Phase II trial with 18 patients showed that 
four patients (22%) experienced clinical benefit from the combination (one partial response 
and three patients who achieved stable disease) (Weroha et al., 2011). In terms of further 
development, a Phase I trial is underway of lapatinib in combination with paclitaxel in 
patients with advanced solid tumors including ovarian tumors (clinicaltrials.gov identifier 
NCT00313599). 
3.3.3 Pertuzumab 
Pertuzumab has been more extensively studied in patients with ovarian cancer than other 
HER2-targeted agents. Studies have included trials of pertuzumab monotherapy as well as 
trials of pertuzumab in combination with other agents (Langdon et al., 2010). In a Phase II 
trial of pertuzumab alone, a partial response was observed in 4% of patients with a further 
7% achieving stable disease for ≥6 months. Interestingly, patients with tumors that had a 
detectable level of HER2 phosphorylation (eight out of 28 tumors tested), had longer 
progression-free survival following pertuzumab treatment than those who did not express 
pHER2 (20.9 vs 5.8 weeks), although this difference was not statistically significant (p=0.14) 
(Gordon et al., 2006). These results, while very preliminary, suggest that pHER2 may 
indicate active HER2 signaling in these tumors and thus benefit from HER2 targeted 
therapy. 
In trials of pertuzumab in combination with carboplatin, gemcitabine, or paclitaxel, patients 
with platinum-sensitive ovarian cancer achieved a 64% response rate compared with 52% for 
patients receiving chemotherapy alone (Kaye et al., 2008; Langdon et al., 2010). Pertuzumab 
has also been tested in combination with gemcitabine versus gemcitabine alone in 130 patients 
with ovarian cancer. A partial response was observed in 14% of patients receiving the 
combination therapy versus 5% receiving gemcitabine alone (Makhija et al., 2010).  
Exploratory biomarker analyses in the Makhija and Kaye studies demonstrated that patients 
with ovarian tumors that express a low level of HER3 mRNA have a better response to 
pertuzumab than those with higher HER3 mRNA levels. Makhija et al. observed that 
patients with low (< median) HER3 mRNA levels receiving pertuzumab and gemcitabine 
demonstrated better response rates than those receiving gemcitabine alone (p=0.0002) 
(Makhija et al., 2010). Kaye et al. reported that in patients with tumors expressing a low level 
of HER3 mRNA who had a treatment-free interval of 6–12 months, those receiving 
pertuzumab had a longer progression-free survival time compared with those who received 
chemotherapy alone; however, this difference was not statistically significant (hazard ratio 
0.55; p=0.16) (Amler, 2010; Kaye et al., 2008).  
3.4 Summary 
Preclinical data demonstrate that HER2 inhibitors reduce tumor cell signaling via HER2 in 
ovarian cancer cells and tumor models. In the clinic, a subset of patients with HER2-positive 
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ovarian tumors responds to HER2-targeted treatment. Studies by Makhija et al. and Kaye et 
al. suggest that measuring the HER3 mRNA level may help to identify a subset of patients 
with ligand-dependent activation of HER2 signaling pathways who may benefit from 
treatment with a combination of pertuzumab and chemotherapy.  
4. The future of the HER family as targets in oncology 
Clinical validation of HER2 as a relevant target in ovarian cancer opens up several 
possibilities for therapeutic development in this area. These include the use of HER family 
antibody conjugates, bispecific antibodies, and novel targeted combinations, all of which are 
likely to require advanced and clinically integrated biomarker strategies to identify 
appropriate patient subsets for treatment.  
HER2 antibodies can be conjugated with other anticancer drugs or radioactive entities to 
target chemotherapy and radiotherapy to cancerous cells that express HER2. Radiolabeled 
trastuzumab and pertuzumab have both been shown to delay tumor progression in mice 
with SKOV3 xenografts (Palm et al., 2007; Persson et al., 2007) and reduce the growth of 
SKOV3 cells in vitro (Heyerdahl et al., 2011), while trastuzumab–platinum (II) conjugates 
have been shown to increase SKOV3 cell death in vitro (Gao et al., 2008). Trastuzumab–DM1 
(T-DM1) conjugates enable the targeted delivery of the antimicrotubule agent DM1 to cancer 
cells overexpressing HER2. In a single-arm Phase II study of T-DM1 therapy, a response rate 
of 26% was observed in 112 patients with HER2-positive metastatic breast cancer (Burris et 
al., 2011). 
The bispecific, trifunctional antibody ertumaxomab, targets HER2 expressed on cancer cells 
and CD3 on T cells, and binds to Fcγ type I/III receptors via its Fc portion. In this way, 
ertumaxomab brings HER2-expressing cells into close contact with T cells and macrophages, 
facilitating antibody-dependent cellular cytotoxicity (ADCC) (Kiewe et al., 2006). In vitro 
studies have also demonstrated that ertumaxomab is able to kill cell lines with low HER2 
expression derived from breast, lung, and colorectal cancers, whereas trastuzumab had no 
cytotoxic effect in these cells (Jager et al., 2009). In a Phase I trial of ertumaxomab in patients 
with HER2-positive metastatic breast cancer, five of 15 patients experienced an antitumor 
response (Kiewe et al., 2006).  
Tumor cells commonly develop resistance to single-agent targeted therapies, thus 
combinations of agents that target different mechanisms of cell proliferation and survival 
often improve response compared with monotherapy alone. For example, the combination 
of trastuzumab with chA21 significantly reduced tumor size in mice with SKOV3 xenografts 
compared with antibody monotherapy (p<0.05) (A. Zhang et al., 2010). Similar results were 
observed with pertuzumab–trastuzumab combinations (Faratian et al., 2011) that have 
shown promise in the clinic (see Section 3.1) (Baselga et al., 2010). However, early clinical 
results for lapatinib and trastuzumab are not as promising. In a clinical trial of 282 patients 
with breast cancer, the combination of 1000 mg lapatinib with trastuzumab did not improve 
progression-free survival compared with 1500 mg lapatinib alone (16.3 versus 12.3 weeks; 
p=0.18) (Wu et al., 2011). Clinical trials of trastuzumab combined with pertuzumab (Baselga 
& Swain, 2010) and T-DM1 combined with pertuzumab (clinicaltrials.gov identifier 
NCT01120184) are ongoing in breast cancer. 
Therapies targeting HER2 can also be combined with EGFR inhibitors in order to block 
multiple signaling pathways. Addition of matuzumab, an EGFR inhibitor, to trastuzumab 
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was shown to reduce tumor progression in mice with SKOV3 xenografts to a greater extent 
than either antibody alone (Larbouret et al., 2007). The combination of trastuzumab or 
pertuzumab with another EGFR inhibitor, cetuximab, significantly inhibited cell growth in 
OVCAR-3 and IGROV-1 cells, although this effect was not observed in SKOV3 cells, 
possibly because of high basal levels of pERK and pAkt (Bijman et al., 2009). A combination 
of cetuximab and trastuzumab has also been shown to inhibit HER2–EGFR dimerization in 
SKOV3 cells, and this effect was shown to improve median survival and the percentage of 
tumor-free animals in a mouse model of ovarian cancer (Gaborit et al., 2011). 
To date, clinical trials of anti-HER2/EGFR combinations have only been performed in non-
ovarian cancer. Trastuzumab has been studies in breast cancer in combination with the 
EGFR inhibitors, gefitinib (Arteaga et al., 2008) and erlotinib (Britten et al., 2009). However, 
the trial of trastuzumab with erlotinib was terminated early, and the study with gefitinib 
showed increased toxicity with no apparent increase in the expected clinical benefit with 
trastuzumab monotherapy. Currently, there is one ongoing Phase I trial of trastuzumab with 
cetuximab in breast cancer (clinicaltrials.gov identifier NCT00367250). Trials are also 
underway to evaluate pertuzumab in combination with erlotinib or cetuximab in several 
types of cancer (clinicaltrials.gov identifiers NCT00947167, NCT01108458, NCT00855894, 
NCT00551421) and patients with CRC are being recruited for a trial of lapatinib in 
combination with cetuximab (clinicaltrials.gov identifier NCT01184482). 
Combining agents that target HER2 with inhibitors of downstream signaling pathway 
components, such as PI3K, mTOR, or MEK, may also lead to increased clinical activity. A 
preclinical study investigating the PI3K inhibitor PKI-587 demonstrated tumor regression in 
xenograft models of breast cancer, which was enhanced when PKI-587 was combined with 
the dual HER2/EGFR tyrosine kinase inhibitor neratinib or a MEK inhibitor, PD0325901 
(Mallon et al., 2011). A number of clinical trials are underway in breast cancer to investigate 
the efficacy of combining trastuzumab with PI3K inhibitors, including BKM120 
(clinicaltrials.gov identifier NCT01132664) and XL-147 (clinicaltrials.gov identifier 
NCT01042925), as well as the combination of neratinib and temsirolimus, an allosteric 
mTOR inhibitor (clinicaltrials.gov identifier NCT01111825). 
Preclinical and early clinical data suggest that targeting HER3 directly may also be 
therapeutically relevant in several types of cancer, including ovarian. The HER3 monoclonal 
antibody MM-121 has been shown to inhibit ovarian tumor growth in vivo (Sheng et al., 
2010) and in vitro studies of another antibody, MM-111, have demonstrated that it inhibits 
cell growth alone and in combination with lapatinib (Oyama et al., 2010) and trastuzumab 
(Huhalov et al., 2010). A Phase I trial of U3-1287 in 31 patients with solid tumors, including 
one patient with ovarian cancer, showed that 26% of patients achieved stable disease for 
≥70 days (Berlin et al., 2011). These antibodies are undergoing early-stage clinical testing in 
combination with other agents including HER2 and EGFR inhibitors (clinicaltrials.gov). 
MEHD7945A a dual-specific antibody targeting HER3 and EGFR has also shown in vivo 
activity in an ovarian xenograft model suggesting a potential benefit of combined inhibition 
of ErbB members (Schaefer et al., 2011).   
4.1 The future use of biomarkers in ovarian cancer 
Preclinical and clinical data suggest that amplification and overexpression of HER2 protein 
or mRNA, while infrequent, clearly exists in some ovarian tumors. Treatment with 
trastuzumab or a HER2 antibody–drug conjugate could be a potential option for these 
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patients. Rare mutations in the HER2 gene may be of particular relevance in ovarian LMP 
tumors where mutations in the BRAF and KRAS oncogenes are also common (see Section 
2.2) (Anglesio et al., 2008). LMP tumors are usually treated successfully with surgery; 
however treatment options are limited in patients who relapse following surgery as this 
tumor type does not respond well to currently available chemotherapy. Further clinical 
evaluation with agents that inhibit HER2 signaling, such as lapatinib or trastuzumab, are 
warranted to determine the benefit of these agents to patients with progressed LMP lesions.  
Based on the available data, it appears that ligand-dependent activation of HER2 signaling 
could be a more important mechanism for HER2 oncogenesis in ovarian cancer. Expression 
of pHER2 or HER3 may also be biomarkers that could identify tumors with oncogenic 
ligand-dependent HER2-activation. Further studies with inhibitors of HER2 dimerization, 
such as pertuzumab, will be useful in assessing their clinical potential in patients with 
ligand-dependent activation of the pathway.  
5. Conclusion 
Targeting HER2 with trastuzumab and lapatinib has proven successful in treating HER2-
positive breast cancer. Other molecules, such as pertuzumab, are in advanced clinical 
development for the treatment of this indication, further validating the clinical relevance 
and importance of this target. In contrast to breast cancer, in which HER2 is overexpressed 
in up to 30% of cases, a much lower proportion of ovarian tumors show activation of HER2 
by this mechanism. Nonetheless, trials of HER2-targeted agents in patients identified with 
HER2-positive ovarian tumors have shown improved progression-free survival and overall 
survival in a small proportion of patients. 
Importantly, there are patients with ovarian tumors with no evidence of HER2 amplification 
or overexpression, but in whom HER2-targted therapeutics appear to be beneficial. In these 
patients, activating mutations in HER2 or high levels of ligand-dependent activation of 
HER2/HER3 signaling may play a more important role in mediating HER2 oncogenesis. 
Identifying these patients through the use of novel biomarkers, such as assessment of HER3 
mRNA levels, could significantly improve the clinical benefit of HER2-targeted therapies in 
this setting. 
In conclusion, the use of targeted HER2 therapies in ovarian cancer warrants further 
investigation, particularly with regard to the development and validation of appropriate 
diagnostic tests. 
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